Laurence Buisseret

Université libre de Bruxelles (ULB)

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (16)

Collaborators (7)

Emanuela Romano

PSL Research University

Christos Sotiriou

Université libre de Bruxelles

Michail Ignatiadis

Christine Desmedt

Head of Laboratory for Translational Breast Cancer Research

John Stagg

Associate Professor

Université de Montréal

Mattia Rediti

Université libre de Bruxelles (ULB)

Alex De Caluwe

Université libre de Bruxelles (ULB)

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Laurence Buisseret

Research Interests

Explore related searches

Contact this professor

Articles (16)

Collaborators (7)

Emanuela Romano

Christos Sotiriou

Michail Ignatiadis

Christine Desmedt

John Stagg

Mattia Rediti

Alex De Caluwe

Make your next move.

Laurence Buisseret

Research Interests

Explore related searches

Contact this professor

Articles (16)

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial

Continuous replenishment of the dysfunctional CD8 T cell axis is associated with response to chemoimmunotherapy in advanced breast cancer

Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: does it help tailor adjuvant treatment?

Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications

The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab

Immunotherapy in breast cancer: an overview of current strategies and perspectives

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges

First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial

Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00

Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma

Publisher Correction: The adenosine pathway in immuno-oncology

The adenosine pathway in immuno-oncology

Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach

The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC)

Collaborators (7)

Emanuela Romano

Christos Sotiriou

Michail Ignatiadis

Christine Desmedt

John Stagg

Mattia Rediti

Alex De Caluwe

Make your next move.